Sentences with phrase «of brain tumor patients»

Not exact matches

The Korle Bu Teaching Hospital has announced the closure of three surgical clinics from February 6, 2016, a move that is set to worsen the plight of brain and spinal tumor patients seeking remedy.

Triple negative patients usually have shorter survival time after diagnosis of brain metastasis, suggesting that these tumor cells adapt much more readily once they've moved to the brain.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

So far, researchers with the Allen Institute for Brain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilBrain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilbrain tumors or epilepsy.

University of Vienna neurologist Karl Dussik measured ultrasound transmissions through patients» heads in an attempt to locate brain tumors.

In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates.

«Although radiosurgery has been shown to be an effective post-surgical treatment for metastatic brain tumors, previous studies did not compare patient outcomes from a single hospital over the same period of time,» said N. Scott Litofsky, M.D., chief of the Division of Neurological Surgery at the MU School of Medicine and senior author of the study.

To illustrate that point, they analyzed a series of 95 patients with a confirmed diagnosis of brain tumor at their department.

Depending on which set of recent recommendations had been followed, neuroimaging would have been delayed or never performed in three to seven percent of patients with brain tumors.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

Researchers from the University of Southampton have discovered a potential way of stopping one of the most aggressive types of brain tumor from spreading, which could lead the way to better patient survival.

The authors conclude, «Unvalidated guidelines to prevent neuroimaging in patients with headaches may reduce the perceived global economic burden at the expense of medical errors, delayed diagnoses, and inferior outcomes for patients with brain tumor.»

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

That could have important implications for patient outcomes, as early diagnosis of brain tumors enables prompt treatment and a wider range of surgical options.

In 11 patients, headache was the only symptom of brain tumor.

In 2002 scientists showed that cytomegalovirus, or CMV, was active in the brain tumors but not the surrounding healthy tissue of all 27 patients they tested who had glioblastoma multiforme.

Baliga's group is also mapping networks in patients with glioblastoma, a particularly deadly type of brain tumor.

Subsequent surgery on vaccinated patients has shown that the T cells are finding and killing tumor cells in the brain, but not enough of them.

Glioblastoma is the most aggressive type of tumor that originates in the brain and with no curative treatments currently available, the average survival time for patients ranges from 15 to 18 months.

Glioblastoma is the most lethal form of primary brain tumor and leads to death in patients by invading the brain tissue in a process that allows single cells to move through normal brain tissue, which makes complete surgical removal of the tumor impossible.

Second, we believe the vaccine may be particularly beneficial for a group of patients with the HLA - A2 type, which suggests that as we move forward, there may be advantages in targeting this population,» said John Yu, MD, vice chair of the Department of Neurosurgery, director of surgical neuro - oncology, medical director of the Brain Tumor Center and neurosurgical director of the Gamma Knife Program at Cedars - Sinai.

Now he and his team are putting cells from human brain tumors into the organoids, which have reached the level of development and complexity of a 20 - week - old human fetus's, to see whether they reprise what happens in patients.

Several days after imaging, the patient underwent brain surgery; using the images as a guide, surgeons safely removed most of her tumor.

Using data from a large public brain tumor database called REMBRANDT, the researchers confirmed that patients with lower levels of SND1 survived longer than those with elevated SND1 expression.

We get heavily hyped drugs like Avastin, which shrank tumors without adding significant time to cancer patients» lives (and increased the incidence of heart failure and blood clots to boot); Avandia, which lowered blood sugar in diabetics but raised the average risk of heart attack by 43 percent; torcetrapib, which raised both good cholesterol and death rates; and Flurizan, which reduced brain plaque but failed to slow the cognitive ravages of Alzheimer's disease before trials were finally halted in 2008.

A pre-surgery tumor size of greater than three centimeters was associated with worse LC, but local recurrence was not significantly affected by the number of brain metastases or the patients» histology or graded prognosis assessments.

Whole brain radiotherapy (WBRT) significantly improves tumor control in the brain after SRS, yet because of its association with cognitive decline, its role in the treatment of patients with brain metastases remains controversial.

In this case, the patient was able to go home the day after the successful removal of multiple brain tumors.»

On the safety side, the panelists delved into the possible risks of injecting genetically modified cells into patients, including the potential for deadly viral infections, brain toxicity, and, paradoxically, the growth of new tumors brought about by CAR - T cells years after treatment.

Patients were stratified by number of brain metastases (1 vs. 2 - 3), primary cancer type (melanoma vs. other histology) and pre-operative tumor size (less than vs. greater than three centimeters).

Storm, who performs surgery on children with brain tumors, added that, «Better understanding of tumor characteristics, as we found in this research, will help guide our surgical planning and clinical decisions for patients with PLGGs in this current era of target - centric clinical trials and personalized medicine.»

Gregory Foltz of Swedish Medical Center in Seattle saw that BEX1 was turned off in the brains of his tumor patients, and using the Brain Atlas, he confirmed that the gene is usually active in healthy brains, as reported in Cancer Research in 2006.

«This is really a big step forward in imaging brain tumors and other issues in young patients,» said Journal of Medical Imaging associate editor Christoph Hoeschen of Otto - von - Guericke Universität.

The researchers performed a pilot study of Dynamic Glucose - Enhanced (DGE) MRI in four normal volunteers and three patients with brain tumors.

Dario C. Altieri, M.D., Wistar's President and CEO and lead author of the study, and colleagues showed how the activation of this pathway leads to an unfavorable prognosis for patients with gliomas — a type of brain tumor — and how the pathway could be a valuable therapeutic target in cancer.

As part of the research, Castro and her colleagues determined that brain tumor cells use the mTOR pathway to hamper the immune response of patients.

Glioblastomal tumors make up about one - quarter of the cases of brain cancer, and most patients survive for no more than 18 months past diagnosis.

The activation of this signaling pathway progressively increased in different types of gliomas, with the highest activity seen in patients with glioblastoma, a particularly difficult - to - treat form of brain cancer that represents approximately 15 percent of all brain tumors.

Past clinical trials of stem cell therapies for chronic stroke patients used cells derived from tumors in humans and brain tissue from fetal pigs.

Working with Seattle, Washington — area neurosurgeons, the Allen Institute acquired healthy cells from the cortex — the outermost layer of the brain that coordinates perception, memory, thoughts, and consciousness — from patients undergoing surgery for epilepsy or brain tumors.

They found that injecting into the carotid artery breast cancer cells that express markers allowing them to enter the brain — cells labelled with bioluminescent and fluorescent markers to enable tracking by imaging technologies — resulted in the formation of many metastatic tumors throughout the brain, mimicking what is seen in advanced breast cancer patients.

They found that injecting patient - derived, brain - seeking melanoma cells into the carotid artery of these preclinical models resulted in the formation of many metastatic tumors throughout the brain, mimicking what is seen in advanced melanoma cancer patients.

At the time, it was thought that this gene fusion was limited to a fraction of brain tumors, affecting about 300 patients in the U.S. per year.

Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Blood clots, often in the legs, are a frequent occurrence in patients fighting glioblastoma, the most common and the most aggressive form of brain cancer. Zerrouqi and http://www.gooakley.com/ Van Meir show that a tumor suppressor gene (p14ARF) that is often mutated in glioblastoma stops them from activating blood clotting.

Many of our brain tumor clinical trials include analysis of the molecular profiles of patients» tumors.

The Bone Marrow and Stem Cell Transplant Program is expanding the use of this technique for patients with solid tumors including neuroblastoma and brain tumors; a variety of high - risk hematologic diseases, such as thalassemia major and transfusion - dependent sickle cell disease; and other nonmalignant diseases.

However these compounds were designed as competitive antagonists to be active in the brain of patients having low concentration of adenosine whereas high levels adenosine are produced by ectonucleotidases, especially CD73 and CD39 that are overexpressed in the tumor microenvironment.

Our clinicians direct the clinical operations of the Children's Health NONC (neuro - oncology) program and are members of the Children's Oncology Group (COG), a national childhood brain tumor consortium that provides our patients access to experimental therapies and new treatment developments.

The researchers examined the protein levels of SOX9 in malignant childhood brain tumors from more than 140 patients together with scientists in Germany.